@article { , title = {Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility)}, abstract = {© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. New treatments are required for severe breathlessness in advanced disease. We conducted a randomised feasibility trial of mirtazapine over 28 days in adults with a modified medical research council breathlessness scale score ≥3. Sixty-four patients were randomised (409 screened), achieving our primary feasibility endpoint of recruitment. Most patients had COPD or interstitial lung disease; 52 (81\%) completed the trial. There were no differences between placebo and mirtazapine in tolerability or safety, and blinding was maintained. Worst breathlessness ratings at day 28 (primary clinical activity endpoint) were, 7.1 (SD 2.3, placebo) and 6.3 (SD 1.8, mirtazapine). A phase III trial of mirtazapine is indicated. Trial registration: ISRCTN 32236160; European Clinical Trials Database (EudraCT no: 2015-004064-11).}, doi = {10.1136/thoraxjnl-2019-213879}, eissn = {1468-3296}, issn = {0040-6376}, issue = {2}, journal = {Thorax}, note = {Estimated acceptance date. Emailed author to ask for date. VEA 29.11.2019 Answer received: The day I sent it or a couple of days before. (email sent 25/11/2019)}, pages = {176-179}, publicationstatus = {Published}, publisher = {BMJ Publishing Group}, url = {https://nottingham-repository.worktribe.com/output/3443583}, volume = {75}, keyword = {COPD Exacerbations, Emphysema, Lung Cancer, Palliative Care, Psychology, COPD Pharmacology, Drug reactions, Idiopathic pulmonary fibrosis}, year = {2020}, author = {Higginson, Irene J. and Wilcock, Andrew and Johnson, Miriam J. and Bajwah, Sabrina and Lovell, Natasha and Yi, Deokhee and Hart, Simon P. and Crosby, Vincent and Poad, Heather and Currow, D.C. and Best, Emma and Brown, S.R.} }